Save time and get answers to complex questions with AI chat
Drugpatentwatch trametinib?Drugpatentwatch crizotinib?Patent expiration date of guselkumab?Somatuline depot patent expiry date?Is allopurinol expensive?
See the DrugPatentWatch profile for vyvanse
Vyvanse (lisdexamfetamine) was approved by the U.S. Food and Drug Administration (FDA) on April 23, 2007. [1]
The FDA approval date above is for the U.S. approval of Vyvanse. The approval is tied to its original branded use for attention-deficit/hyperactivity disorder (ADHD) in children and adults. [1]
Patent and exclusivity timelines are calculated from filing/other events (not just the first approval date), so exact expiry depends on the specific patent and exclusivity type. DrugPatentWatch.com tracks these details for Vyvanse. [2] Sources: [1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021977 [2] https://www.drugpatentwatch.com/p/vyvanse
Other Questions About Vyvanse :